Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) EBIT Margin (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed EBIT Margin for 15 consecutive years, with 31432.3% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin fell 3045328.0% year-over-year to 31432.3%, compared with a TTM value of 3785.07% through Sep 2025, down 57931.0%, and an annual FY2024 reading of 2881.59%, up 755789.0% over the prior year.
  • EBIT Margin was 31432.3% for Q3 2025 at BioRestorative Therapies, down from 1089.77% in the prior quarter.
  • Across five years, EBIT Margin topped out at 979.02% in Q3 2024 and bottomed at 126537.95% in Q4 2022.
  • Average EBIT Margin over 5 years is 28300.69%, with a median of 16687.47% recorded in 2023.
  • The sharpest move saw EBIT Margin plummeted -8048702bps in 2021, then skyrocketed 10985047bps in 2023.
  • Year by year, EBIT Margin stood at 80185.34% in 2021, then plummeted by -58bps to 126537.95% in 2022, then skyrocketed by 87bps to 16687.47% in 2023, then skyrocketed by 63bps to 6212.8% in 2024, then plummeted by -406bps to 31432.3% in 2025.
  • Business Quant data shows EBIT Margin for BRTX at 31432.3% in Q3 2025, 1089.77% in Q2 2025, and 19230.14% in Q1 2025.